A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer · NSCLC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 184 (planned)
- Started
- Nov 18, 2024
- Main results expected
- Dec 4, 2029
- Fully finished
- Dec 27, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major Pathologic Response (MPR) rate as determined by central Blinded Independent Pathology Review (BIPR)
Measured over: Up to 12 weeks
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Up to 9 weeks
Occurrence of TEAEs leading to death
Measured over: Up to 9 weeks
Occurrence of TEAEs leading to treatment discontinuation
Measured over: Up to 9 weeks
Occurrence of Serious Adverse Events (SAEs)
Measured over: Up to 9 weeks
Occurrence of grade ≥3 laboratory abnormalities
Measured over: Up to 9 weeks
Number of participants unable to receive cemiplimab and chemotherapy for 2 consecutive cycles due to REGN10597-related toxicities during the first 3 cycles
Measured over: Up to 9 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06465329 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC